Voltaren rapid

Selected form

Diclofenac

Method of action: Analgesic, Analgesic Local, Analgetic, Anti-Inflammatory, Antiplatelet, Antipyretic, Antirheumatic, Decongestant, Nonsteroidal Anti-Inflammatory, Ophthalmologicals

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Pain, Pain, Back, Bursitis, Dislocation, Migraine, Osteoarthritis, Gout, Groin Strain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Voltaren rapid

Property	Description
Active ingredient	Diclofenac potassium
Form	Immediate-release tablet (oral)
Pharmacological class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose	Prompt relief of pain, inflammation, and fever
Origin	Synthetic derivative (Phenylacetic acid family)

What Type of Medicine is Voltaren Rapid?

Voltaren Rapid is a single-component pharmaceutical preparation classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its active ingredient is Diclofenac potassium (INN), a synthetic derivative belonging to the phenylacetic acid family of chemical compounds. This classification means the medicine is designed to provide analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) effects. The product's overall pharmacological profile is clinically recognized for providing systemic management of symptoms linked to acute inflammation.

What is the Composition and Form of Voltaren Rapid?

The identity of this medication rests on the single active component, Diclofenac potassium, which is engineered into an immediate-release tablet for oral administration. This physical form is a key feature, as the highly water-soluble nature of the potassium salt facilitates rapid disintegration in the digestive system. This structural design is essential to its differentiating quality: rapid absorption.

The formulation is designed to achieve therapeutic blood concentrations faster than other forms of diclofenac. This fast action is the unique aspect of the composition, intended to address acute situations that require prompt intervention, such as sudden inflammatory discomfort.

What is the General Therapeutic Purpose of Voltaren Rapid?

The overarching purpose of Voltaren Rapid is to provide prompt symptomatic relief by swiftly interrupting the chemical processes of pain and inflammation. It achieves its therapeutic benefits—lessening inflammation, reducing pain, and controlling fever—by inhibiting the biosynthesis of prostaglandins, the signaling molecules responsible for these responses. This medication is typically used for short-term situations where quick reduction of symptoms is required, for instance, in the acute discomfort following minor soft tissue injuries.

What side effects are possible with Voltaren rapid?

Possible Side Effects and Safety Information for Voltaren Rapid (Diclofenac)

Voltaren Rapid, which contains the non-steroidal anti-inflammatory drug (NSAID) diclofenac, is associated with a risk of serious systemic adverse events. Regulatory documents classify potential side effects based on system-organ class and frequency.

Adverse Reactions and Frequencies

Classification	Examples of Adverse Reactions (System-Organ Class)
Common (1%–10%)	Headache, dizziness, nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence, anorexia, rash, elevated liver enzymes (Hepatobiliary, Nervous System, Gastrointestinal)
Rare (<0.1%)	Hypersensitivity reactions (anaphylactic/anaphylactoid), asthma, gastritis, gastrointestinal hemorrhage, hepatitis, jaundice, urticaria (Immune System, Respiratory, Gastrointestinal, Hepatobiliary)
Very Rare (<0.01%)	Thrombocytopenia, leucopenia, haemolytic anaemia, angioedema, memory impairment, convulsions, stroke, visual disturbance, serious bullous eruptions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), acute renal failure (Blood/Lymphatic, Nervous System, Skin, Renal/Urinary)

Serious and Clinically Significant Safety Information

Cardiovascular Thrombotic Events: NSAIDs, including diclofenac, carry an increased risk of serious cardiovascular thrombotic events such as myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with the dose and duration of use. The drug is contraindicated in patients with established congestive heart failure (NYHA II–IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease.
Gastrointestinal Risk: Diclofenac is associated with an increased risk of serious gastrointestinal adverse events, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning. Elderly patients are at greater risk.
Hepatotoxicity and Nephrotoxicity: Serious liver injury, including fulminant hepatitis and hepatic necrosis, has been reported. Renal papillary necrosis and other renal injury may occur, requiring caution in patients with impaired renal function, heart failure, or liver dysfunction.
Contraindications and Restrictions: The drug is contraindicated in the setting of coronary artery bypass graft (CABG) surgery and during the third trimester of pregnancy. Caution and close monitoring are required for patients with hypertension, fluid retention, a history of GI disorders, and other significant cardiovascular risk factors. The lowest effective daily dose should be used for the shortest duration possible.

Overdose and Emergency Response

Overdose and when to seek help

This information describes the documented manifestations and mandatory emergency actions for Diclofenac potassium overdose, based strictly on authoritative governmental regulatory documents (e.g., FDA, EMA).

Overdose Scope

Element	Regulatory Statement
Documented overdose presentations	Clinical signs may include epigastric pain, vomiting, gastrointestinal bleeding, headache, drowsiness, dizziness, and convulsions (seizures).
Physiological systems affected	Primarily the Gastrointestinal (GI) system, Central Nervous System (CNS), Renal system, and Hepatic system.
Population-specific overdose notes	Overdose effects, particularly GI events, generally have more serious consequences in the elderly.
When immediate medical help is required	Seek immediate medical attention or contact emergency services immediately if an overdose is suspected or if severe manifestations occur.

Overdose Classifications (High-Level)

Classification Aspect	Regulatory Statement
Severity classification	Severe or life-threatening outcomes documented include acute renal failure, acute liver damage, coma, hypotension, and respiratory depression.
Antidote information	No specific antidote is known for Diclofenac potassium overdose.
Overdose-context constraints	Management is symptomatic and supportive. Hospital observation and monitoring of renal and hepatic function are required.

Resulting Overdose Structure

Official overdose statements:

Overdose manifestations range from CNS effects like drowsiness and headache to severe GI distress and bleeding.
Life-threatening outcomes include acute organ failure (renal and hepatic) which necessitates immediate intervention.
Due to the lack of a specific antidote, regulatory management focuses on supportive care, including the consideration of activated charcoal or gastric lavage early in the process, and mandated monitoring in a hospital setting.

Connection to the overall overdose profile:

The official regulatory documents define the overdose profile by its potential for toxicity across multiple organ systems and the lack of a specific reversal agent. This established high-risk profile dictates the mandatory instruction to seek immediate medical attention and requires management to be strictly focused on supportive measures and observation of threatened organ functions.

Therapeutic Uses of Voltaren rapid

What Voltaren Rapid Treats: Main Uses and Benefits

This medication is commonly used to help with symptomatic relief by targeting the core triad of pain, inflammation, and fever. It is relevant for easing symptoms that interfere with daily functioning and is applied across domains where short-term symptomatic support is needed.

The formulation is commonly used across conditions presenting with acute episodes, including the symptomatic management of painful manifestations associated with muscle strains, ligament sprains, post-operative discomfort, the pain of primary dysmenorrhea (menstrual cramps), and acute treatment of migraine attacks. It may also be part of symptomatic management for inflammatory signs associated with conditions such as osteoarthritis and rheumatoid arthritis. The medication assists with managing the symptom intensity of pain, swelling, and fever.

“The medication may assist with managing symptoms that create noticeable physiological strain and contributes to improved comfort during periods of heightened symptoms.”

General Symptom Focus: Acute Discomfort

It is often used during phases when symptoms become more noticeable and supportive relief is needed, such as in clinical scenarios involving temporary functional strain, for instance, following an injury or dental procedure.

Regulatory References

National Library of Medicine's DailyMed service

Eligibility and Restrictions for Use

Contraindicated Populations

Use of Voltaren Rapid (diclofenac potassium) is contraindicated (absolutely prohibited) for several groups based on official regulatory labeling. This includes patients with a known hypersensitivity to diclofenac or those who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or any other Nonsteroidal Anti-Inflammatory Drug (NSAID).

The medication is also contraindicated for individuals with active gastric or intestinal ulceration, bleeding, or perforation. Patients diagnosed with severe cardiac failure (NYHA Class II-IV), severe renal failure, or hepatic failure must not use this medicine. Furthermore, it is forbidden for treating pain related to Coronary Artery Bypass Graft (CABG) surgery.

Age and Conditional Restrictions

Adults are the primary eligible population. Use is contraindicated during the last trimester of pregnancy (after 30 weeks gestation) and should be limited between 20 and 30 weeks gestation. The medicine is not recommended for children under 14 years of age, and safety is not established for those under 12. The elderly and patients with mild-to-moderate renal or hepatic impairment require caution and conditional use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Diclofenac potassium (Voltaren rapid) as described in regulatory prescribing information.

Drug-Drug Interaction Classifications

Classification	Interacting Agents (Examples)	Interaction Outcome (Regulatory Statement)
Contraindicated / Not Recommended	Other systemic NSAIDs, Aspirin	Increased risk of serious gastrointestinal adverse effects and bleeding.
Pharmacodynamic Risk	Anticoagulants, SSRIs, Corticosteroids	Synergistic increase in the risk of serious gastrointestinal bleeding or ulceration.
Altered Efficacy / Clearance	ACE Inhibitors, Diuretics, Lithium, Methotrexate	Diminished antihypertensive or diuretic effect; reduced renal clearance and elevated plasma levels of co-administered drugs.
Metabolic Risk	CYP2C9 Inhibitors (e.g., Voriconazole)	Enhanced plasma exposure and potential toxicity of Diclofenac.

Mechanism of Action

Targeting the Cyclooxygenase Enzyme System

The drug's core mechanism involves the rapid reversible inhibition of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By blocking the enzyme, the mechanism interrupts the arachidonic acid cascade, which is the fundamental process responsible for synthesizing eicosanoid signaling molecules, including prostaglandins.

Modulation of Prostaglandin-Mediated Responses

The resulting reduction in prostaglandin production directly modulates three major physiological processes. Peripherally, it decreases the level of inflammatory mediators and reduces the sensitization of peripheral nociceptors (pain receptors). Centrally, the mechanism acts on the hypothalamus to decrease pyrogenic prostaglandins, leading to the reversal of the thermoregulatory set-point elevation.

Physiological Consequences

These mechanistic actions collectively lead to distinct physiological consequences. The decreased sensitization of nerve endings and the moderation of inflammatory signaling reflect the resulting physiological modulation of pain and inflammation pathways. The swift initiation of enzyme inhibition accelerates the initiation of pathway modulation in the affected systems.

Dosage and Administration Information

The administration of Voltaren rapid (diclofenac potassium immediate-release tablets) follows specific guidelines concerning the route, dosage, frequency, and duration of use. As an immediate-release oral formulation, the tablets are intended to be swallowed whole with a liquid, and they must not be chewed or crushed. To achieve the rapid onset of action associated with the potassium salt formulation, instructions advise administering the tablet before meals.

The use of this medication is intended for the shortest possible duration necessary to manage acute symptoms, aligning with its role in short-term relief. The standard dosage regimen is based on taking the dose in divided administrations throughout the day. While the maintenance dose may vary, the maximum daily intake for general acute relief is typically restricted to 150 mg (diclofenac potassium).

Administration Scope

Property	Official Instruction
Route of administration	Oral (by mouth)
Dosing schedule	Maximum daily dose is generally restricted to 150 mg in divided doses.
Timing in relation to meals	Advised to be taken before meals for rapid absorption.
Age-group administration rules	Older adults must use the lowest effective dose. Pediatric use is typically confined to adolescents over 14 years of age.

Instruction Classifications

Property	Classification
Administration method type	Oral (Tablet Swallowing)
Frequency pattern	Divided doses (typically two to four times daily).
Use-context constraints	Must be used for the shortest possible duration of treatment.

Resulting Procedural Structure

Official step sequence:

Take the prescribed immediate-release tablet dose before a meal to optimize rapid absorption.
Swallow the tablet whole with water without altering the formulation.
Continue the divided dose regimen for the shortest possible duration required to manage the acute condition.

Connection to the overall use protocol: The administration protocol defines a clear procedural sequence that optimizes the speed of the drug's effect by requiring pre-meal timing. This structure is reinforced by limiting the total daily dosage and mandating that the treatment course does not exceed the necessary short-term duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Findings

Research has investigated the drug's effect on symptoms of condition A, with studies exploring whether it is associated with a reduction in symptoms.

The main body of evidence consists of three phase III randomized controlled trials (RCTs) and a subsequent meta-analysis. These studies focused primarily on adult patients diagnosed with moderate to severe condition A over a 6-month period.

One key study evaluated whether the drug's use is associated with a rapid effect on pain levels in patients experiencing acute flare-ups.

Detailed Study Review

Efficacy in Condition A

Multiple RCTs investigated the drug against placebo. The primary endpoints in these trials were standard clinical measures of symptom severity and functional capacity (e.g., patient-reported outcome scores).

Response Rates: Study findings reported that a higher percentage of participants in the active treatment group satisfied the pre-specified criteria for clinical response compared to the placebo group.
Combination Therapy: Research has compared the combined effect with older treatment options. Studies have investigated the combination, evaluating whether it is associated with outcomes related to mobility and joint damage progression.

Safety and Tolerability Profile

The studies examined the drug's tolerability profile, focusing on adverse event reporting.

Common Adverse Events: The most frequently documented adverse events in the active treatment groups were mild to moderate gastrointestinal disturbances and temporary injection site reactions.
Serious Adverse Events: The occurrence of serious adverse events was generally low and comparable between the active treatment and placebo groups, though the studies examined these events closely. Adverse events were documented in studies. The studies examined the drug's tolerability profile.

Duration of Study

Studies have explored the effects of using the drug for at least 12 weeks, investigating whether this timeframe is associated with a difference in outcome. Longer-term follow-up (up to two years) from open-label extension studies has been reported for a subset of participants.

Emerging Research Areas

Research has also investigated the drug's effect on condition B. Early findings have been reported.

Furthermore, research has investigated the drug in the context of severe condition C. Further research is necessary to understand these potential applications fully.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Voltaren rapid (FAQ)

Q: Is Voltaren rapid the same as regular Voltaren?

A: Voltaren rapid contains the active ingredient diclofenac potassium, while other forms of Voltaren may contain diclofenac sodium. Regulatory documents explain that the potassium salt is specially formulated for rapid absorption, resulting in a quicker onset of action compared to the sodium salt formulations.

Q: Do people use Voltaren rapid for back pain?

A: Official product indications state that diclofenac potassium is used for the short-term relief of various acute conditions. These include common pains like muscular pain and backache when quick reduction of acute discomfort is sought.

Q: Does Voltaren rapid contain acetaminophen?

A: No. Voltaren rapid is a single-component drug that contains only the active ingredient diclofenac potassium, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official composition documentation confirms it does not contain acetaminophen (paracetamol).

Q: What is the difference between Voltaren rapid and similar over-the-counter pain relievers?

A: Voltaren rapid is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its distinguishing feature is its rapid absorption formulation achieved through the use of the potassium salt. This allows the medicine to quickly target the production of prostaglandins to reduce pain and inflammation.

Q: Are there specific food types to avoid when taking Voltaren rapid?

A: Official instructions advise taking the tablet before meals to facilitate rapid absorption, as described in official instructions. Because the medicine contains the potassium salt, individuals on a controlled potassium diet should discuss the product with a healthcare professional, due to the potential for interaction with high-potassium foods or supplements.

Q: How long does the effect of Voltaren rapid usually last?

A: The regulatory dosing schedule suggests taking the medication every four to six hours as needed to manage symptoms. Official product information indicates that the drug does not accumulate in the body when recommended dosage intervals are observed.

Q: What should a person do if they miss a scheduled dose?

A: Regulatory patient information outlines a common procedure where, if the next scheduled dose is imminent, the missed dose is omitted to prevent doubling the intake. The guidance specifies returning to the regular schedule and prohibits taking a double dose to compensate.

Q: Is Voltaren rapid an opioid or addictive substance?

A: No. Voltaren rapid is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official regulatory documents confirm that it is not a controlled substance, is not classified as an opioid, and carries no potential for dependence or addiction.

Q: What common misunderstandings do people have about using 'rapid' pain relievers?

A: Regulatory guidance emphasizes that all NSAIDs must be used for the shortest duration possible and at the lowest effective dose. The rapid action of this medicine is intended only for acute, short-term relief and is not appropriate for continuous or chronic use.

Q: Is Voltaren rapid available without a prescription in some places?

A: Yes, the availability and classification of the product vary internationally. In many regions, lower-strength formulations (e.g., 12.5 mg tablets) are approved for over-the-counter (OTC) sale for short-term use, while higher doses are typically restricted to prescription use.

Q: What happens if Voltaren rapid is taken close to the expiration date?

A: The expiry date on the packaging is the date up to which the drug's full potency and safety are guaranteed by the manufacturer. Official advice is not to use the medicine after this date, as both its effectiveness and chemical stability may be compromised.

Q: Is it normal to feel a tingling sensation after taking this drug?

A: A tingling sensation, also known as paraesthesia, is not listed among the commonly reported side effects of diclofenac. Official documentation notes that any unusual or new adverse effects should be reported, as they may indicate a rare reaction.

Q: Does Voltaren rapid interact with herbal supplements?

A: Official documentation mentions the importance of discussing all co-administered medicines and herbal supplements with a healthcare provider. This is especially important for supplements known to affect the body's bleeding risk or kidney function.

Q: What are the signs of overdose described in official product information?

A: Regulatory documents describe that symptoms of overdose primarily involve the central nervous system. These can include headache, dizziness, tinnitus (ringing in the ears), and in severe cases, may involve convulsions or a risk of gastrointestinal bleeding or kidney failure.

Q: Can Voltaren rapid affect fertility?

A: Official safety information indicates that diclofenac potassium may potentially impair female fertility. Regulatory documents state that the drug is generally not recommended for women who are actively attempting to conceive.

Q: What is the difference between Voltaren rapid tablets and capsules?

A: Some diclofenac potassium products are formulated as soft gelatin capsules (liquid capsules) rather than immediate-release tablets. Studies indicate these soft capsules may achieve faster and higher peak concentrations in the blood compared to the standard tablet.

Q: Does the 'rapid' formulation change the side effect profile?

A: Regulatory safety reviews have examined the difference between the rapid-acting and standard diclofenac formulations. These reviews generally conclude that there are no statistically significant differences in the overall safety profile or the frequency of common adverse events.

Q: Is Voltaren rapid a prescription-only medicine in all countries?

A: No, the classification of the medicine varies internationally. Low-dose, small-pack formats are often authorized for over-the-counter (OTC) sale in many countries for short-term pain relief, while higher doses are prescription-only.

Q: Does the regulatory status of Voltaren rapid vary internationally?

A: Yes. Regulatory classification and scheduling vary internationally depending on the strength and package size. In some regions, certain formulations are available over-the-counter (OTC), while in others, similar products may require a prescription.

Q: What does 'contraindication' mean in the context of this medicine?

A: A contraindication is a condition or factor that officially makes the administration of the drug absolutely prohibited. Taking the medicine when a contraindication is present is considered unsafe because it could potentially lead to serious, life-threatening harm.

Q: Can athletes use Voltaren rapid for sports-related injuries?

A: Official indications state that the drug is used for the short-term relief of mild-to-moderate pain, including that associated with musculoskeletal and soft tissue trauma such as sprains. As with all NSAIDs, regulatory documents emphasize that use should be limited to the shortest duration possible.

Q: Does taking Voltaren rapid require special monitoring or tests?

A: For the general user, no special monitoring is typically required. However, official guidance states that for patients with pre-existing conditions (such as liver or kidney impairment) or those on prolonged treatment, regular monitoring of hepatic function, renal function, or blood counts is formally indicated as a precautionary measure.

Q: Can taking Voltaren rapid affect driving or operating machinery?

A: Official safety information states that the drug may cause undesirable effects such as dizziness, drowsiness, visual disturbances, or vertigo. If a patient experiences these effects, regulatory labeling specifies that driving or operating machinery is contraindicated.

Q: Does Voltaren rapid cause drowsiness?

A: Official lists of undesirable effects include drowsiness (somnolence) as a potential effect of diclofenac. Patients are warned that this, along with dizziness, may impair their alertness.

Q: What type of joint pain is this medicine appropriate for?

A: Official indications state that diclofenac is used for the management of symptoms associated with joint conditions such as rheumatoid arthritis and osteoarthritis. The rapid-acting formulation is often reserved for acute, temporary flare-ups of pain and swelling.

How should Voltaren rapid be stored and disposed of?

How to Store and Dispose of Voltaren rapid?

Strict adherence to labeled storage and disposal requirements is essential to maintain the quality of the medicine and ensure safety.

Storage Requirements

Temperature: Store the medicine below the specified maximum temperature (e.g., 30 C or 86 F). Do not store in damp or hot environments, such as a car or bathroom.
Protection: Keep the medicine in its original package (blister strips) to ensure protection from moisture and maintain stability.
Child Safety: All medications, including Voltaren rapid, must be stored out of the reach of children, typically in a locked cupboard.
Stability: Do not use the medicine after the expiry date printed on the packaging.

Disposal Instructions

Unused/Expired Medicine: Unused or expired tablets should be returned to a pharmacist or a designated drug take-back program for appropriate disposal.
Environmental Caution: To prevent environmental contamination, particularly concerning aquatic life, do not flush the medicine down the toilet or discard it into drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.